感染症治療の世界市場分析:HIV感染、インフルエンザ、マラリア、結核、肝炎、HPV感染

Grand View Researchが発行した調査報告書(GVIEW709120)
◆英語タイトル:Infectious Disease Therapeutics Market Analysis By Disease Type (HIV infection, Influenza, Malaria, Tuberculosis, Hepatitis, and HPV infection), By Region, And Segment Forecasts, 2014 - 2025
◆商品コード:GVIEW709120
◆発行会社(リサーチ会社):Grand View Research
◆発行日:2017年8月
◆ページ数:81
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD4,950 ⇒換算¥559,350見積依頼/購入/質問フォーム
Multi UserUSD7,950 ⇒換算¥898,350見積依頼/購入/質問フォーム
Global/corporate LicenseUSD9,950 ⇒換算¥1,124,350見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGrand View Research社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Grand View Research社の概要及び新刊レポートはこちらでご確認いただけます。

Grand View Researchが発行した本調査レポートでは、感染症治療の世界市場について調査・分析し、感染症治療の世界市場動向、感染症治療の世界市場規模、市場予測、セグメント別感染症治療市場分析、主要地域別市場規模、競争状況、関連企業情報などを含め、以下の構成でお届け致します。
【レポートの概要】

The global top 6 infectious disease therapeutics market is expected to reach USD 86.2 billion by 2025, according to a new report by Grand View Research, Inc. The market is primarily driven by increasing number of Human Immunodeficiency Virus (HIV), Human Papillomavirus (HPV), TB, and hepatitis cases globally.
Government and private organizations are investing heavily in the healthcare sector to prevent, diagnose, and treat infectious diseases; rising investments for development of new drugs to treat infectious diseases, and increasing number of initiatives for creating awareness about these conditions are expected to boost the market during the forecast period. Furthermore, increasing number of patent expirations and entry of generic drugs in the market are expected to increase the demand for infectious disease therapeutics due to their low prices.

In addition, availability of reimbursement for diagnosis & treatment of these infections and free distribution of drugs by manufacturers in regions with high incidence of these diseases are factors further expected to propel the market growth. However, low penetration rate of anti-infective and availability of large number of counterfeit drugs are expected to restraint the market growth during the forecast period.

North American market held the largest share in 2016. Presence of large number of manufacturers, favorable reimbursement scenario, and increasing healthcare expenditure are major factors responsible for the largest share held by this region. However, Asia Pacific is likely to grow at the highest rate between 2017 and 2025. High prevalence of infectious diseases; improving economic conditions in Asian countries, rising government initiatives to increase the adoption of treatments for infectious diseases, and rising funding activities are factors that can be attributed for the highest growth rate of this region during the forecast period.

Further Key Findings From the Report Suggest:

• The HIV therapeutics segment held the largest revenue share in 2016 due to high number of HIV cases globally

• North America dominated the global market owing to the strong reimbursement framework coupled with high adoption rate of treatments for infectious diseases

• The HPV therapeutics segment is estimated to grow at the highest rate during the forecast period

• Some of the key players areNovartis AG, Gilead, GlaxoSmithKline plc, Janssen Pharmaceutical, Inc., F. Hoffmann-La Roche Ltd., BioCryst Pharmaceuticals, Inc., and Boehringer Ingelheim GmbH

【レポートの目次】

Table of Contents

Chapter 1 Research Methodology
1.1 Information Procurement
1.2 Data Analysis
Chapter 2 Executive Summary
2.1 Market Snapshot
Chapter 3 Infectious Disease Therapeutics Market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.2 Market Driver Analysis
3.2.1 Rising funding activities by various organizations
3.2.2 Increasing prevalence of infectious diseases
3.2.3 Growing awareness activities by non-profit organizations
3.2.4 Patent expiration of branded drugs is expected to increase the availability of drugs
3.3 Market Restraint Analysis
3.3.1 Lack of reimbursement in selected countries
3.3.2 Low penetration rates of diagnosis and treatment
3.4 Penetration & Growth Prospect Mapping
3.5 Top 6 infectious disease therapeutics Market – SWOT Analysis, by Factor (Political & legal, Economic and Technological)
3.6 Industry Analysis – Porter’s
Chapter 4 Infectious Disease Therapeutics Market: Disease Type Estimates & Trend Analysis
4.1 Top Six Infectious Disease Therapeutics Market: Disease Type Movement Analysis
4.2 HIV
4.2.1 HIV market estimates and forecasts, 2014 – 2025 (USD Million)
4.2.2 HIV market estimates and forecasts, by drug type 2014 – 2025 (USD Million)
4.3 Influenza
4.3.1 Influenza market estimates and forecasts, 2014 – 2025 (USD Million)
4.3.2 Influenza market estimates and forecasts, by drug type 2014 – 2025 (USD Million)
4.4 Hepatitis
4.4.1 Hepatitis market estimates and forecasts, 2014 – 2025 (USD Million)
4.5 Tuberculosis
4.5.1 TB market estimates and forecasts, 2014 – 2025 (USD Million)
4.5.2 TB market estimates and forecasts, by drug type 2014 – 2025 (USD Million)
4.6 Malaria
4.6.1 Malaria market estimates and forecasts, 2014 – 2025 (USD Million)
4.6.2 Malaria market estimates and forecasts, by drug type 2014 – 2025 (USD Million)
4.7 HPV
4.7.1 HPV market estimates and forecasts, 2014 – 2025 (USD Million)
Chapter 5 Infectious Disease Therapeutics Market: Regional Estimates & Trend Analysis, and By Product
5.1 Top Six Infectious Disease Therapeutics Market: Regional Movement Analysis
5.2 North America
5.2.1 Market estimates & forecasts, 2014 – 2025 (USD Million)
5.2.2 U.S.
5.2.2.1 Market, by disease type estimates & forecasts, 2014 – 2025 (USD Million)
5.2.3 Canada
5.2.3.1 Market, by disease type estimates & forecasts, 2014 – 2025 (USD Million)
5.3 Europe
5.3.1 Market estimates & forecasts, 2014 – 2025 (USD Million)
5.3.2 UK
5.3.2.1 Market, by disease type estimates & forecasts, 2014 – 2025 (USD Million)
5.3.3 Germany
5.3.3.1 Market, by disease type estimates & forecasts, 2014 – 2025 (USD Million)
5.4 Asia Pacific
5.4.1 Market estimates & forecasts, 2014 – 2025 (USD Million)
5.4.2 Japan
5.4.2.1 Market, by disease type estimates & forecasts, 2014 – 2025 (USD Million)
5.4.3 China
5.4.3.1 Market, by disease type estimates & forecasts, 2014 – 2025 (USD Million)
5.5 Latin America
5.5.1 Market estimates & forecasts, 2014 – 2025 (USD Million)
5.5.2 Brazil
5.5.2.1 Market, by disease type estimates & forecasts, 2014 – 2025 (USD Million)
5.5.3 Mexico
5.5.3.1 Market, by disease type estimates & forecasts, 2014 – 2025 (USD Million)
5.6 Middle East and Africa (MEA)
5.6.1 Market estimates & forecasts, 2014 – 2025 (USD Million)
5.6.2 South Africa
5.6.2.1 Market, by disease type estimates & forecasts, 2014 – 2025 (USD Million)
Chapter 6 Competitive Landscape
6.1 Company Profiles
6.1.1 Gilead Sciences, Inc.
6.1.1.1 Company overview
6.1.1.2 Financial performance
6.1.1.3 Product benchmarking
6.1.1.4 Strategic initiatives
6.1.2 GlaxoSmithKline plc
6.1.2.1 Company overview
6.1.2.2 Financial performance
6.1.2.3 Product benchmarking
6.1.3 Janssen Pharmaceutical
6.1.3.1 Company overview
6.1.3.2 Financial performance
6.1.3.3 Product benchmarking
6.1.3.4 Strategic initiatives
6.1.4 F. Hoffmann-La Roche AG
6.1.4.1 Company overview
6.1.4.2 Financial performance
6.1.4.3 Product benchmarking
6.1.5 BioCryst Pharmaceuticals, Inc
6.1.5.1 Company overview
6.1.5.2 Financial performance
6.1.5.3 Product benchmarking
6.1.5.4 Strategic initiatives
6.1.6 Boehringer Ingelheim GmbH
6.1.6.1 Company overview
6.1.6.2 Financial performance
6.1.6.3 Product benchmarking
6.1.6.4 Strategic initiatives
6.1.7 Novartis International AG
6.1.7.1 Company overview
6.1.7.2 Financial performance
6.1.7.1 Product benchmarking
6.1.7.4 Strategic initiatives
6.1.8 Merck & Co., Inc.
6.1.8.1 Company overview
6.1.8.2 Financial performance
6.1.8.1 Product benchmarking
6.1.8.4 Strategic initiatives

List of Tables

TABLE 1 Number of people living with HIV and % of HIV population on ART
TABLE 2 HBV and HCV epidemic in WHO regions in 2015
TABLE 3 HIV therapeutics market estimates & forecasts, by drug type, 2014 - 2025 (USD Million)
TABLE 4 TB therapeutics market estimates & forecasts, by drug type, 2014 - 2025 (USD Million)
TABLE 5 Malaria therapeutics market estimates & forecasts, by drug type, 2014 - 2025 (USD Million)
TABLE 6 Influenza therapeutics market estimates & forecasts, by drug type, 2014 - 2025 (USD Million)
TABLE 7 North America top six infectious disease therapeutics market estimates & forecasts, by type, 2014 - 2025 (USD Million)
TABLE 8 U.S. top six infectious disease therapeutics market estimates & forecasts, by disease type, 2014 - 2025 (USD Million)
TABLE 9 Canada top six infectious disease therapeutics market estimates & forecasts, by disease type, 2014 - 2025 (USD Million)
TABLE 10 Europe top six infectious disease therapeutics market estimates & forecasts, by disease type, 2014 - 2025 (USD Million)
TABLE 11 UK top six infectious disease therapeutics market estimates & forecasts, by disease type, 2014 - 2025 (USD Million)
TABLE 12 Germany top six infectious disease therapeutics market estimates & forecasts, by disease type, 2014 - 2025 (USD Million)
TABLE 13 Asia Pacific top six infectious disease therapeutics market estimates & forecasts, by disease type, 2014 - 2025 (USD Million)
TABLE 14 Japan top six infectious disease therapeutics market estimates & forecasts, by disease type, 2014 - 2025 (USD Million)
TABLE 15 China top six infectious disease therapeutics market estimates & forecasts, by disease type, 2014 - 2025 (USD Million)
TABLE 16 Latin America top six infectious disease therapeutics market estimates & forecasts, by disease type, 2014 - 2025 (USD Million)
TABLE 17 Brazil top six infectious disease therapeutics market estimates & forecasts, by disease type, 2014 - 2025 (USD Million)
TABLE 18 Mexico top six infectious disease therapeutics market estimates & forecasts, by disease type, 2014 - 2025 (USD Million)
TABLE 19 MEA top six infectious disease therapeutics market estimates & forecasts, by disease type, 2014 - 2025 (USD Million)
TABLE 20 South Africa top six infectious disease therapeutics market estimates & forecasts, by disease type, 2014 - 2025 (USD Million)




List of Figures

FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Primary research pattern
FIG. 4 Market research approaches
FIG. 5 Value chain based sizing & forecasting
FIG. 6 QFD modelling for market share assessment
FIG. 7 Market snapshot (USD Million), 2016
FIG. 8 Market trends & outlook
FIG. 9 Market segmentation & scope
FIG. 10 Market driver relevance analysis (Current & future impact)
FIG. 11 Market restraint relevance analysis (Current & future impact)
FIG. 12 Penetration & growth prospect mapping
FIG. 13 SWOT Analysis, By Factor (political & legal, economic and technological)
FIG. 14 Porter’s Five Forces Analysis
FIG. 15 Top 6 infectious disease therapeutics market: disease type outlook and key takeaways (USD Million)
FIG. 16 Top 6 infectious disease therapeutics market: disease type movement analysis (USD Million)
FIG. 17 HIV market estimates and forecasts, 2014 - 2025 (USD Million)
FIG. 18 Hepatitis market estimates and forecasts, 2014 - 2025 (USD Million)
FIG. 19 Influenza market estimates and forecasts, 2014 - 2025 (USD Million)
FIG. 20 Malaria market estimates and forecasts, 2014 - 2025 (USD Million)
FIG. 21 TB market estimates and forecasts, 2014 - 2025 (USD Million)
FIG. 22 HPV market estimates and forecasts, 2014 - 2025 (USD Million)
FIG. 23 Regional market place: Key takeaways (USD Million)
FIG. 24 Top 6 infectious disease therapeutics market: regional movement analysis (USD Million)
FIG. 25 North America top six infectious disease therapeutics market estimates & forecasts, 2014 - 2025 (USD Million)
FIG. 26 The U.S. top six infectious disease therapeutics market estimates & forecasts, 2014 - 2025 (USD Million)
FIG. 27 Canada top six infectious disease therapeutics market estimates & forecasts, 2014 - 2025 (USD Million)
FIG. 28 Europe top six infectious disease therapeutics market estimates & forecasts, 2014 - 2025 (USD Million)
FIG. 29 UK top six infectious disease therapeutics market estimates & forecasts, 2014 - 2025 (USD Million)
FIG. 30 Germany top six infectious disease therapeutics market estimates & forecasts, 2014 - 2025 (USD Million)
FIG. 31 Asia Pacific top six infectious disease therapeutics market estimates & forecasts, 2014 - 2025 (USD Million)
FIG. 32 Japan top six infectious disease therapeutics market estimates & forecasts, 2014 - 2025 (USD Million)
FIG. 33 China top six infectious disease therapeutics market estimates & forecasts, 2014 - 2025 (USD Million)
FIG. 34 Latin America top six infectious disease therapeutics market estimates & forecasts, 2014 - 2025 (USD Million)
FIG. 35 Brazil top six infectious disease therapeutics market estimates & forecasts, 2014 - 2025 (USD Million)
FIG. 36 Mexico top six infectious disease therapeutics market estimates & forecasts, 2014 - 2025 (USD Million)
FIG. 37 MEA top six infectious disease therapeutics market estimates & forecasts, 2014 - 2025 (USD Million)
FIG. 38 South Africa top six infectious disease therapeutics market estimates & forecasts, 2014 - 2025 (USD Million)

【レポートのキーワード】

感染症治療、HIV感染、インフルエンザ、マラリア、結核、肝炎、HPV感染

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 感染症治療の世界市場分析:HIV感染、インフルエンザ、マラリア、結核、肝炎、HPV感染(Infectious Disease Therapeutics Market Analysis By Disease Type (HIV infection, Influenza, Malaria, Tuberculosis, Hepatitis, and HPV infection), By Region, And Segment Forecasts, 2014 - 2025)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆